Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pharmaron Beijing Co's
Operating Income
for the
three
months ended in Mar. 2026 was €62 Mil. Pharmaron Beijing Co's Interest Expense for the
three
months ended in Mar. 2026 was €-6 Mil.
Pharmaron Beijing Co's interest coverage for the quarter that ended in Mar. 2026 was 9.62.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pharmaron Beijing Co's Interest Coverage or its related term are showing as below:
FRA:17Q1'
s Interest Coverage Range Over the Past 10 Years
Min: 6.01 Med: 10.26 Max: 45.47
Current: 11.35
FRA:17Q1's Interest Coverage is ranked worse than 75.8% of 376
companies
in the Biotechnology industry
Industry Median: 106.135
vs FRA:17Q1: 11.35
Pharmaron Beijing Co (FRA:17Q1) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pharmaron Beijing Co Interest Coverage Related Terms
Pharmaron Beijing Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:17Q1 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Interest Coverage falls into.
Pharmaron Beijing Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (FRA:17Q1) has a Interest Coverage of 9.62 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharmaron Beijing Co and its competitors. This is near median its historical median of 10.26. Over the past decade, Pharmaron Beijing Co's Interest Coverage has ranged from 6.01 to 45.47. According to the industry distribution chart, Pharmaron Beijing Co ranks #285 out of 376 companies in the Biotechnology industry, placing it in the top 75.8%.
Is Pharmaron Beijing Co's Interest Coverage too high?
Pharmaron Beijing Co's current Interest Coverage of 9.62 is near median its 10-year median of 10.26. Over the past 10 years, this metric has ranged from a low of 6.01 to a high of 45.47. The Biotechnology industry median Interest Coverage is 106.14. Pharmaron Beijing Co's value of 9.62 is 90.9% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #285 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #285 out of 376 companies for Interest Coverage. This places Pharmaron Beijing Co in the lower half of its industry. The industry median Interest Coverage is 106.14. Pharmaron Beijing Co's value of 9.62 is 90.9% below this benchmark. Historically, Pharmaron Beijing Co's own Interest Coverage has ranged from 6.01 to 45.47 over the past decade. While the company's 10-year median is 10.26 vs. the industry median of 106.14, Pharmaron Beijing Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current Interest Coverage of 9.62 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current Interest Coverage is 9.62, which is near median its own 10-year median of 10.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (FRA:17Q1) has a current Interest Coverage of 9.62. The stock's GF Value™ is €2.23, compared to a current price of €2.58 — trading 15.7% above its estimated fair value. The current Interest Coverage is 9.62, which is near median its 10-year median of 10.26 and 90.9% below the Biotechnology industry median of 106.14. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pharmaron Beijing Co (FRA:17Q1), the current Interest Coverage is 9.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of €2.58 is trading 15.7% above its estimated GF Value™ of €2.23.
Key valuation signals for FRA:17Q1:
Interest Coverage: 9.62 (near median its 10-year median of 10.26)
GF Value™: €2.23 vs. price of €2.58 (15.7% above fair value)
Industry Position: 90.9% below the Biotechnology median (#285 of 376)
No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for FRA:17Q1
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17Q1 has been successfully added to your 
